Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains)

Diagnostic Microbiology and Infectious Disease

Volumn 76, Issue 2, 2013, Pages 239-240

  Jones, Ronald N ^a   Stilwell, Matthew G ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Streptococci; ABSSSI; Dalbavancin; Lipoglycopeptides; Rarer species; Viridans group

Indexed keywords

DALBAVANCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; CORYNEBACTERIUM; DRUG POTENCY; DRUG SCREENING; GRAM STAINING; IN VITRO STUDY; LISTERIA MONOCYTOGENES; MICROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS DYSGALACTIAE; STREPTOCOCCUS GROUP C; STREPTOCOCCUS GROUP F; STREPTOCOCCUS GROUP G; STREPTOCOCCUS MILLERI; STREPTOCOCCUS MITIS; STREPTOCOCCUS MUTANS; STREPTOCOCCUS SALIVARIUS;

ANTI-BACTERIAL AGENTS; CORYNEBACTERIUM; HALF-LIFE; LISTERIA MONOCYTOGENES; MICROBIAL SENSITIVITY TESTS; MICROCOCCUS; STREPTOCOCCUS; TEICOPLANIN;

EID: 84877798586     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.01.002     Document Type: Article

References (14)

1. Bennett J.W., Lewis J.S., Ellis M.W. Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Ther Clin Risk Manag 2008, 4:31-40.
2. Biedenbach D.J., Bell J.M., Sader H.S., Turnidge J.D., Jones R.N. Activities of dalbavancin against a worldwide collection of 81,673 Gram-positive bacterial isolates. Antimicrob Agents Chemother 2009, 53:1260-1263.
3. Billeter M., Zervos M.J., Chen A.Y., Dalovisio J.R., Kurukularatne C. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 2008, 46:577-583.
4. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2012, CLSI, Wayne, PA. ninth edition.
5. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 23rd informational supplement 2013, CLSI, Wayne, PA.
6. Goldstein E.J., Citron D.M., Merriam C.V., Warren Y., Tyrrell K., Fernandez H.T. In vitro activities of dalbavancin and nine comparator agents against anaerobic Gram-positive species and Corynebacteria. Antimicrob Agents Chemother 2003, 47:1968-1971.
7. Heine H.S., Purcell B.K., Bassett J., Miller L., Goldstein B.P. Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. Antimicrob Agents Chemother 2010, 54:991-996.
8. Jauregui L.E., Babazadeh S., Seltzer E., Goldberg L., Krievins D., Frederick M., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005, 41:1407-1415.
9. Jones R.N., Flamm R.K., Sader H.S. Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagn Microbiol Infect Dis 2013, 10.1016/j.diagmicrobio.2013.01.003.
10. Jones R.N., Fritsche T.R., Sader H.S., Goldstein B.P. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J Chemother 2005, 17:593-600.
11. Raad I., Darouiche R., Vazquez J., Lentnek A., Hachem R., Hanna H., et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis 2005, 40:374-380.
12. Seltzer E., Dorr M.B., Goldstein B.P., Perry M., Dowell J.A., Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003, 37:1298-1303.
13. Streit J.M., Fritsche T.R., Sader H.S., Jones R.N. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004, 48:137-143.
14. Zhanel G.G., Calic D., Schweizer F., Zelenitsky S., Adam H., Lagace-Wiens P.R., et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010, 70:859-886.